Panion Animal Health AB develops an innovative treatment for epilepsy in dogs and targets the American market first. On the 22nd of October 2018, Panion held a pre-submission conference with the US-FDA in Washington DC, where the development product was presented for authority reviewers from both the FDA’s Center for Veterinary Medicine (CVM) and other authority centers. Panion had five persons involved in the meeting; regulatory FDA-expert Dave Petrick, Director of Business Development Carlos N. Velez, and CEO Anja Holm, who were supported by two of Panion’s scientific experts over the telephone.